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Abstract 
The case was 79-year-old female with type 2 diabetes mellitus (T2DM) and other medical problems who has been treated on insulin 
for Multiple Daily Injections (MDI). She has recently developed cough and was diagnosed as slight bronchopneumonia, followed by 
the admission to the hospital with intensive treatment. Simultaneously, she could not control her usual daily life, and then her diabetic 
therapy was changed to Xultophy. It is the combined agent of liraglutide and insulin degludec that can be injected once a day. In this 
article, the clinical progress and some discussion from various points of view would be described. 
Keywords: Multiple daily insulin injection (MDI); Xultophy; Type 2 Diabetes Mellitus (T2DM); Bio-psycho-social; Glucagon like 
peptide-1 receptor agonist (GLP-1RA) 
Introduction 
The prevalence of diabetes has been increasing in the world. It is 
usually associated with non-communicable diseases (NCDs), such 
as obesity, metabolic syndrome, nonalcoholic fatty liver disease 
(NAFLD), and so on (Met-S) [1]. For the treatment for these 
diseases, adequate nutritional therapy and weight control would 
be required. As regard to Type 2 diabetes mellitus (T2DM), it is 
important to reduce several risks of macroangiopathy and 
microangiopathy [2]. In other words, optimal control of daily 
profile of blood glucose, adequate treatment for diabetes using 
oral hypoglycemic agents (OHAs) and/or injectable agents are 
important, as well as patient-oriented medical goal [3]. 
Concerning the therapy for T2DM, the basic principle is adequate 
nutritional treatment. For previous decade, the usual diet therapy 
was calorie restriction (CR), in which fat food was limited for 
reducing total calorie. After various nutritional practice and 
research, low carbohydrate diet (LCD) was introduced for 
effective way of managing T2DM [4]. Clinical efficacy of LCD 
has been proposed with several studies for years in European and 
North American regions [5,6]. On the other hand, authors and 
collaborators have started LCD in Japan and developed LCD 
therapy in Japan until now [7]. We established Japan LCD 
Promotion Association (JLCDPA), and continued development of 
LCD medically and socially through many opportunities for 
workshops, seminars, medical societies and books [8]. For 
practical use, three recommended type of LCD have been 
informed broadly. They are super LCD, standard LCD and petite 
LCD with carbohydrate ratio as 12%, 26%, and 40%, respectively 
[9]. Moreover, clinical research has been continued with several 
medical themes, such as daily profile of blood glucose, 
insulinogenic index (IGI), Morbus (M) value, meal tolerance test 
(MTT), continuous glucose monitoring (CGM) and clinical 
application of Xultophy [10]. In the light of pharmacological 
agents, several kinds of glucagon like peptide-1 receptor agonists 
(GLP-1RAs) have been used in the diabetic therapy [11]. For 
example, there are liraglutide, dulaglutide, lixisenatide, exenatide, 
and others [12]. Among some research for GLP-1RAs, Network 
Meta-Analysis (NMA) showed the useful evaluation clinically for 
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diabetic control and also some outcomes for atherosclerotic 
cardiovascular disease (ASCVD) [13]. As a result, the effect of 
cardiometabolic benefits was found by using GLP-1RA regimens. 
In the group of GLP-1RA agents, liraglutide has been effective 
and rather widely applied to diabetic patients. Related to this 
prevalence, Xultophy has been made and used for actual practice 
as the combination of liraglutide and insulin degludec [14]. When 
compared with either one agent each, this combined agent 
revealed better effect [15]. GLP-1RA brings the improved 
findings for reducing fasting plasma glucose and postprandial 
glucose [16]. Furthermore, basal insulin brings the improved 
result for decreasing fasting plasma glucose, and this combined 
agent with fixed ratio can lead improved general diabetic control 
by injection once per day. In addition, Xultophy has the efficacy 
to maintain cardioprotective activity by improving the function of 
beta cell in the pancreas [17]. Diabetic practice and research for 
years concerning CGM, MMT, Xultophy and others. Among our 
experience, a female elderly case receiving the treatment of 
Xultophy was found. She showed the effect of Xultophy, as well 
as the meaningful perspective from bio-psycho-social points of 
view. Xultophy may be useful in the light of patient-oriented 
medicine which is the recommended goal for medical practice. In 




When she was 59 years old, she was pointed out to have type 2 
diabetes mellitus (T2DM). After that, she had several diseases 
until 69 years old, including hypertension, atrial fibrillation (Af), 
hyperlipidemia, cerebral infarction in the left thalamus to slight 
degree and gastro esophageal reflux disease (GERD). 
Successively, she had developed arthralgia of large joints, and 
was diagnosed as rheumatoid arthritis (RA) at the age of 70 years 
old. When she was around 75 years old, she complained of left 
low back pain, associated with the diagnosis of left ureteral stone, 
bilateral renal stone and osteoporosis. Her arthralgia has been 
controlled by small doses of prednisolone 5 mg/day for the 
treatment of RA during 70 to 79 years old. Regarding the medical 
history from Feb 2017 to Nov 2020, she received a simple 
operation of abdominal wall scar hernia. Endoscopic examination 
was performed once a year for upper gastrointestinal tract, which 
showed reflux esophagitis (GERD grade D). The results on Feb, 
2021 included i) GERD grade D (reflux esophagitis), ii) hiatal 
hernia slippery type, severe, iii) chronic active gastritis (atrophic 
gastritis) C-III, yellow tumor in the stomach, and iv) subduodenal 
mucosa, which are not particularly problematic. 
Present history 
She has been diabetic for 20 years and taking insulin for 1 year. In 
late Dec 2020, her lower body became weakened, which caused 
her to fall down a few times. This episode brought her back pain 
and inability to get up. She was transferred to Tokushima Red 
Cross Hospital (TRCH) and was proved to show low blood 
glucose as 55 mg/dL. On her spine XP, compression fractures 
were found in three locations, Th12, L4, and L5. Head CT shows 
periventricular hyperlucency and many small previoius lacuna 
infarcts in the basal ganglia. Chest XP showed mild 
bronchopneumonia in the upper right lobe. No obvious fever was 
observed, SpO2 was in the normal range, and Ceftriaxone Sodium 
Hydrate (CTRX) 1g was administered every 12 hours for some 
days. Gradually, her general condition improved, and she was 
transferred to Hayashi hospital. In the past few months, she has 
been difficult to properly manage insulin injections by MDI, 
because she could not inject properly predetermined units of 
insulin. 
Current insulin treatment 
She has a long history of diabetes and has recently received 
insulin treatment. After hospitalization in late Dec 2020, she had 
Multiple Daily Injections (MDI) to control blood glucose [18]. 
The long-acting insulin used was administered with glargine once 
before bedtime, and the fast-acting insulin was administered with 
insulin human three times daily before meals. As to insulin units, 
insulin human was given three times a day by the sliding scale 
procedure at pre-prandial time [19]. The method was as follows. 
i) 61-80 mg/dL: glucose 10g per os, ii) 81-200 mg/dL human 0 
unit, iii) 201-250 mg/dL: 2 units, iv) 251-300 mg/dL: 4 units, v) 
301-350 mg/dL: 6 units, vi) 351- mg/dL <: 8 units. In fact, the 
diurnal variation in blood glucose was 107-215-217-274 mg/dL, 
which was poorly controlled. 
Physical examination 
Consciousness is alert, and speech is ordinary. Vitals showed 
pulse rate 67/min, and blood pressure 130/67 mmHg. Her 
physique showed 148 cm in height, 68kg in weight, 31 kg/m2 in 
body mass index (BMI) with ideal body weight (IBW) as 48.2kg. 
Physicals showed that lung vesicular, heart no significant 
murmurs, abdomen soft, flat, no tenderness, bowel sound audible. 
Neurological findings showed unremarkable. 
Several examinations 
The results of several examinations on admission to Hayashi 
Hospital were as follows. Hb 10.2 g/dL, RBC 422 x 106 /μL, Ht 
32.5%, MCV 77 fL (80-98), MCH 24.2 pg (27-34), MCHC 31.4 
g/dL (31-36), WBC 8800 /μL, Plt 35.2 x 104 /μL, BUN 27 mg/dL, 
Cr 1.41 mg/dL, uric acid 6.6 mg/dL, eGFR 28 mL/min/1.73m2, 
TG 75 mg/dL, HDL-C 51 mg/dL, LDL-C 87 mg/dL, T-C 153 
mg/dL, TP 5.9 g/dL, Alb 3.3 g/dL, A/G ratio 1.27, Alb 55.9%, α1-
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glb 4.0%, α2-glb 11.5%, β-glb 11.8%, γ-glb 16.8%, AST 13 U/L, 
ALT 7 U/L, γ-GT 13 U/L, ALP 199 U/L, LDH 229 U/L (100-
340), LAP 41 U/L (30-70), ChE 198 U/L (213-501), T-Bil 0.5 
mg/dL, CK 69 U/L (41-153), amylase 48 U/L (35-125), CRP 3.15 
mg/dL, HBs Ag negative, TSH 5.9 μIU/mL (0.35-4.94), free T4 
1.16 ng/dL (0.7-1.48). Concerning diabetes, HbA1c 8.0%, fasting 
blood glucose 116 mg/dL, Urinary C-peptide 24.4 μg/day (23-
155), urinary albumin 199 mg/day (2-20). Other examinations 
except blood tests were as follows: Hasegawa Dementia Scale-
Revised (HDS-R) 20 points (22-30). Mini-Mental State 
Examination (MMSE) 20 points (20/30). Chest X-P showed mild 
pulmonary congestion with CTR 55%. Electrocardiogram (ECG) 
showed atrial fibrillation (Af). Several tests included that no 
retinopathy in fundus, nerve conduction velocity (NCV) within 
normal limits, the coefficients of variation of RR intervals (CV-
RR) 1.95%, abdominal echo showed chronic liver disease and 
hemangioma in the segment 5 (10 x 7 x 10mm), ankle brachial 
index (ABI) 1.13/1.19. cardio-ankle vascular index (CAVI) 
10.0/10.0. 
Table 1: Changes in daily profile of blood glucose for MDI and Xultophy. 
Date  Daily profile 
of Blood 
Glucose 
   Treatment  
 morning noon evening night Xultophy Human Glargine 
 (mg/dL) (mg/dL) (mg/dL) (mg/dL) (doses) (unit) (unit) 
-7 107 186 304 228  0-0-6-2 4 
-6 99 217 264 202  0-2-4-2 4 
-5 100 280 206 276  0-4-2-4 4 
-4 96 309 119 257  0-6-0-4 4 
-3 99 241 188 236  0-2-0-2 4 
-2 109 256 181 236  0-4-0-2 4 
-1 98 276 157 273  0-4-0-4 4 
1 92  230  5   
2 96  270  5   
3 100  282  6   
4 111  232  6   
5 92  225  6   
6 87  233  7   
7 87  300  7   
8 104  241  7   
9 93  295  8   
10 88  190  8   
11 95  210  8   
12 75  174  8   
13 79  226  8   
14 86  230  8   
15 69  discharge  8   
Problems and prescription 
From mentioned above, current medical problems are 
summarized in the following. #1 T2DM: MDI treatment, #2 
bronchopneumonia: antibiotics given, #3 compression fractures of 
spine: (Th12, L4, L5). #4 RA: prednisolone 5mg/day 
administration, #5 Af, #6 GERD: grade D (reflux esophagitis). 
The prescriptions concerning medical problems include 
amlodipine besilate (Amlodine ®) 5mg 1T, prednisolone 
(Predonin ®) 5mg 1T, edoxaban tosilate hydrate (Lixiana ®) 
30mg 1T, celecoxib (Celecox ®) 100mg 4T /day, rebamipide 
(Mucosta ®) 100mg 3T /day, suvorexant (Belsomra ®) 10mg 1T 
vds. As an evaluation of nutritional status, mild undernutrition is 
observed from the decreased data in TP, Alb, and A / G ratios, 
and anemia is observed from a low Hb value. Meals during 
hospitalization include 1600 kcal / day, protein 59 g / day, and 
water 1362 ml / day. In addition, there are moderate nutritional 
risks, mild undernutrition, obesity and anemia. The meal content 
was set to 1600 kcal, protein 59 g, water 1362 ml, and salt 6.2 g 
or less per day. 
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Clinical course 
It was difficult for the patient to perform MDI completely due to 
the sliding scale three times a day. Several reasons were present, 
such as i) existing rather dementia of the patient, ii) the 
cooperation of the family is difficult during the daytime, and 
others. Consequently, the treatment for glucose variability was 
decided to start injection of Xultophy, which can be injected once 
a day. It started on January 25th at 5 doses of Xultophy. The 
changes of the glucose daily profile during the clinical course was 
summarized in Table 1. As a result, the application of Xultophy 
seemed to bring satisfactory glucose control. The successful 
results have encouraged the patient and also the family to 
continue diabetic therapy with Xultophy associated with adequate 
regular lifestyle. When she was discharged from the hospital, the 
infection was completely cured and diabetes control was good. 
The value of HbA1c during Dec 2020 to Feb 2021 was 8.0%, 
7.1% and 7.2%, respectively. The prescription at discharge was i) 
ipragliflozin L-proline (Sugra ®) 50 mg / day, ii) azilsartan 
(Azilva ®) 20 mg 1T, iii) suvorexant (Belsomra ®) 10 mg 1T 1 x 
vds, iv) vonoprazan fumarate (Takecab ®) 10 mg 1T (Table 1). 
Discussion 
Historically, diabetic treatment has been developed including oral 
hypoglycemic agents (OHAs) and some kinds of injections such 
as insulin and GLP-1RA. For better control of glucose variability, 
insulin treatment was recommended as the regimen of basal-bolus 
injection [20]. For further natural changes in glucose and insulin, 
multiple daily injection (MDI) was recommended for standard 
method of controlling blood glucose as possible. It is indeed that 
it is ideal situation, but continuous 3-4 times daily injections seem 
to be taken too much efforts for the diabetic patient and family. 
Recent topic includes clinical introduction of Xultophy to patients 
with T2DM, which seems to be effective, convenient and useful 
way of regimen [14]. Some consecutive studies of clinical effect 
of Xultophy are observed, that is the European Xultophy 
Treatment Retrospective Audit (EXTRA) study. There was a real-
word evidence (RWE) study (EXTRA) from the European 
diabetes centers [21]. As a result, significant decrease of HbA1c 
level (0.7%) and weight reduction (2.4 kg) for 6 months were 
found in the cases who have changed the treatment from MDI to 
Xultophy. EXTRA study has included more than 600 cases in 5 
countries. The results showed that initiation treatment brought 
0.9% HbA1c decrease for 6 months (p<0.001) [22]. From these 
data, Xultophy was estimated to reveal effective and useful 
injectable agent, as well as convenient regular lifestyle of the 
patient and the family. This case was firstly admitted to the 
diabetes department in a large hospital and had been treated with 
MDI. When her clinical situation became stable, she was 
transferred to our hospital. The MDI method is certainly ideal for 
glycemic control, but it is not easy to continue in her daily life 
[18]. During hospitalization, medical staffs can help management 
of MDI treatment with sliding scale method. However, when the 
patient is at home, it is not easy to continue it for the patient and 
family. In this case, the treatment was changed from MDI to 
Xultophy once a day. The first amount were 5 doses. The 
standard method of administration of Xultophy is to start with 16 
doses in the patients with already treated on insulin [14]. When 
the patient is naïve for using insulin, the recommended doses 
would be 10 doses. However, there seem to be different situation 
between Western countries and Eastern countries. Authors have 
some clinical experiences to control glucose variability by 
Xultophy with small doses [23]. With reference to our former 
cases, this case was started to be provided Xultophy from small 
doses. After that, we increased the doses of Xultophy up to 8 
doses, where the profile of blood glucose became rather stable. 
The case is elderly patient associated with several medical 
problems, then we did not intend to maintain the strict control of 
diabetes. Another factor would be present. The case has been 
taking prednisolone for the anti-inflammatory effect against RA. 
Based on her medical history, she was diagnosed as T2DM 20 
years ago, and was diagnosed as RA 9 years ago. Then, she 
started to be taken prednisolone. From this history, it is suggested 
that the elevated blood glucose may be from several causes, 
including i) the presence of primary T2DM, ii) inflammatory 
influence of RA and iii) secondary influence of steroid 
administration [24]. Current diurnal fluctuations in blood glucose 
show lower in the morning and higher in the evening. If the time 
period of providing prednisolone changes, the daily profile of 
blood glucose may change [23]. When a diabetic patient is taking 
steroids for RA, it is difficult to evaluate detail glucose variability 
because hyperglycemia is influenced from both of diabetes and 
steroids. From Pubmed database, complete literature search was 
conducted for all relative reports [25]. The combined keywords 
included DM, insulin, hyperglycemia, glucocorticoids therapy, 
glucose-lowering drugs, SGLT-2i, GLP-1RA, DPP-4i. Related to 
these factors, further accumulation of data would be expected for 
future investigation and analysis. This case seemed to have 
characteristic glycemic variability. She was satisfactory pre-
prandial glucose level in the early morning. However, post-
prandial glucose level in the afternoon was rather higher. For 
improving this tendency, provided dose in Xultophy was 
increased, but rather hyperglycemia was persisted. Possible 
reason may be included from the medical history and laboratory 
data. She has chronic inflammatory situation due to RA, and 
decreased values of TP, albumin, A/G ratio. From these, possible 
existence of liver dysfunction may bring the influence of 
converting glucose into glycogen associated with reduced 
restoring function [26]. Consequently, overloaded glucose may 
flow into blood vessels, which causes acute glucose elevation 
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after meal period [27]. If the patient has impaired liver function, 
gluconeogenesis in the liver would be decreased. Consequently, 
glucose level would be lower in the early morning [28]. 
Regarding the background of the case, detail situation would be 
evaluated from three aspects which are bio-psycho-social axes 
[29]. The first is bio-axis. For stable control of blood glucose, a 
series of treatments called blood glucose measurement-sliding 
scale method-MDI is ideal. However, it seems to be not easy as a 
matter of fact. From the clinical effect of Xultophy, a satisfactory 
level of therapeutic efficacy is expected. The second is psycho-
axis [30]. The patients themselves are elderly and managing the 
MDI method can be a hassle. In addition, there is a borderline 
condition for dementia and/or mild cognitive impairment (MCI). 
Based on the above, the application of Xultophy is recommended. 
The third is social-axis. It is preferable that the patient's family 
can contribute to the coverage of the treatment to some extent. 
For this point, it is difficult for the family to cooperate with the 
MDI method. On the other hand, the injection of Xultophy once a 
day has the advantage of possible assistance. Considering the 
mentioned axes above, Xultophy is considered to be preferable 
news for elderly diabetic patients. Regarding the course of HbA1c 
in this case, it was stable at 7.1-7.2% in Feb-Mar 2021. There are 
some limitations in this report. We report here one case with 
satisfactory results of Xultophy administration from various 
points of view. Further accumulation of cases would be required 
for future research. Medical staffs have to consider the 
background of the patient such as family situation. Xultophy is 
reported to have wide beneficial efficacy and further detail 
investigation will be expected [31]. In summary, a patient with 
T2DM was treated with Xultophy and several perspectives were 
discussed. For older diabetic patients, Xultophy would be 
probably recommended for better control of glucose variability 
and for improved daily life form bio-psycho-social points of view. 
This report becomes hopefully a reference for diabetic clinic and 
research in the future. 
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